Natick, MA-based Karyopharm Therapeutics has banked $48.2 million in Series B cash. The funds will be used to advance its pipeline of selective inhibitors of nuclear export (SINE) drug candidates for hematologic and solid tumors. An unnamed private investor joined additional investors and Delphi Ventures in coming up with the money. "This significant capital infusion will allow us to advance our lead drug candidate KPT-330 (currently in Phase I studies) in two oncology indications through full clinical development," stated Michael Kauffman, the CEO of Karyopharm. Release